Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

701.23 +18.30 (+2.68%)
Official Closing Price Updated: 7:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results
The Danish drug giant reported a 22% weight loss over 36 weeks. 
Via Investor's Business Daily
2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher
Via The Motley Fool
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
Via The Motley Fool
Topics Earnings
My Top 5 Stocks to Buy in Early 2025
Via The Motley Fool
5 Stocks On Sale: Values Or Traps?
Lots of stocks can look cheap, especially after a sell-off. They may even have a low price-to-earnings (P/E) ratio. But that doesn’t mean the stock is a “value”. 
Via Talk Markets
Topics Stocks / Equities
Maxwell Biosciences Announces Appointment of José Antonio Alas to Its Board of Directors
Austin, Texas--(Newsfile Corp. - January 22, 2025) - Maxwell Biosciences ("Maxwell"), a pre-clinical drug platform company that develops Claromers™, ... 
Via Newsfile
Is Novo Nordisk Stock a Buy?
Via The Motley Fool
How Is The Market Feeling About Eli Lilly?
 
Via Benzinga
Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play
GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions 
Via MarketBeat
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end. 
Via Benzinga
Stock Of The Day: Lilly's Strong Support Level Signals Potential Rebound
Stock of the Day: Eli Lilly & Co. (LLY) is rebounding from Friday's sales disappointment, finding support at $722 and set for another uptrend. 
Via Benzinga
Healthcare And Biotech Stocks Lag The Market Again
Biotech stocks got little help from the JPM Conference despite some recovery to the general market. 
Via Talk Markets
Topics Stocks / Equities
Eli Lilly's Options: A Look at What the Big Money is Thinking
 
Via Benzinga
Here's How Much $1000 Invested In Eli Lilly 15 Years Ago Would Be Worth Today
 
Via Benzinga
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX,... 
Via Benzinga
Should You Buy the Dip in Eli Lilly Stock Right Now?
Shares of pharmaceutical stock Eli Lilly are cratering after the company lowered its sales guidance for Q4. 
Via The Motley Fool
Eli Lilly Missed Sales Expectations Again. Should Investors Be Worried?
Via The Motley Fool
3 Unstoppable Stocks to Buy in 2025
Via The Motley Fool
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Via The Motley Fool
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company. 
Via Benzinga
Topics Government
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
Novo Nordisk Stock Tumbles As Ozempic Faces US Pricing Scrutiny, Semaglutide Trial Underwhelms: Retail Gets Anxious
Though negotiated prices won't take effect until 2027, the inclusion of semaglutide has raised concerns about Novo's revenue and potential ripple effects on Eli Lilly's rival drugs. 
Via Stocktwits
Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value
Here are three low-priced stocks you can buy today that are positioned in sector that make them solid choices to double in 2025 
Via MarketBeat
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks
Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with unknowns. 
Via Investor's Business Daily
Topics Government
FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease
FDA approves Eli Lilly's Omvoh for Crohn's disease, showing strong Phase 3 results in clinical remission and intestinal healing over two years. 
Via Benzinga
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
These companies lead their respective markets, making them must-haves for buy-and-hold dividend investors. 
Via The Motley Fool
Could Donald Trump Make Eli Lilly Stock a No-Brainer Buy in 2025?
Via The Motley Fool
Topics Government
9 of the 10 Largest Companies in the World Are Making Big Moves Into AI. Here's Why Investors Should Pay Attention.
Via The Motley Fool
Topics Artificial Intelligence
My 10 Top Stocks to Buy to Start the New Year Off Right
Via The Motley Fool
Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall
Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance. 
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.